Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENGN enGene	$4.62 -2.7%	$3.73	$2.65 ▼ $11.00	$236.08M	-0.41	85,341 shs	24,873 shs
IMA ImageneBio	$13.40 -0.4%	$15.55	$11.65 ▼ $23.28	$53.87M	0.51	13,670 shs	2,166 shs
OGI Organigram Global	$1.73	$1.46	$0.85 ▼ $2.00	$231.91M	1.45	738,182 shs	830,261 shs
TLSA Tiziana Life Sciences	$1.81 -1.1%	$1.83	$0.63 ▼ $2.60	$211.50M	-0.57	591,348 shs	167,938 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENGN enGene	+9.45%	+21.48%	+37.68%	+22.74%	-27.15%
IMA ImageneBio	-1.32%	-4.40%	-11.45%	-4.94%	-35.54%
OGI Organigram Global	+3.59%	+10.19%	+22.70%	+30.89%	-5.98%
TLSA Tiziana Life Sciences	-1.08%	-5.18%	-6.63%	+37.59%	+53.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENGN enGene	3.2433 of 5 stars	3.5	5.0	1.7	2.5	0.6
IMA ImageneBio	3.256 of 5 stars	3.3	0.0	3.3	3.3	1.3
OGI Organigram Global	0.6094 of 5 stars	0.0	2.0	2.7	0.0	1.3
TLSA Tiziana Life Sciences	0.7074 of 5 stars	0.0	3.0	2.9	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENGN enGene	3.00	Buy	$23.29	404.02% Upside
IMA ImageneBio	2.50	Moderate Buy	$35.50	164.93% Upside
OGI Organigram Global	0.00	N/A	N/A	N/A
TLSA Tiziana Life Sciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest IMA, OGI, TLSA, and ENGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/25/2025	IMA ImageneBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$25.00 ➝ $23.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENGN enGene	N/A	N/A	N/A	N/A	$5.35 per share	N/A
IMA ImageneBio	$9.16M	5.88	N/A	N/A	$28.83 per share	0.46
OGI Organigram Global	$223.82M	1.04	N/A	N/A	$2.08 per share	0.83
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	$0.04 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENGN enGene	-$55.14M	-$1.65	N/A	N/A	N/A	N/A	-32.60%	-28.26%	9/10/2025 (Estimated)
IMA ImageneBio	-$49.23M	-$7.68	N/A	N/A	N/A	N/A	-23.94%	-21.62%	N/A
OGI Organigram Global	-$33.39M	$0.05	34.61	N/A	N/A	2.86%	-8.19%	-5.79%	N/A
TLSA Tiziana Life Sciences	-$11.86M	N/A	0.00	∞	N/A	N/A	N/A	N/A	10/13/2025 (Estimated)

Latest IMA, OGI, TLSA, and ENGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/10/2025	Q3 2025	ENGN enGene	-$0.5084	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q3 2025	OGI Organigram Global	-$0.01	-$0.03	-$0.02	-$0.03	$68.04 million	$50.49 million
7/24/2025	Q2 2025	IMA ImageneBio	-$0.14	-$0.06	+$0.08	-$0.06	N/A	N/A
6/10/2025	Q2 2025	ENGN enGene	-$0.4768	-$0.51	-$0.0332	-$0.51	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENGN enGene	N/A	N/A	N/A	N/A	N/A
IMA ImageneBio	N/A	N/A	N/A	N/A	N/A
OGI Organigram Global	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENGN enGene	0.09	12.66	12.66
IMA ImageneBio	N/A	13.52	13.52
OGI Organigram Global	N/A	2.59	1.42
TLSA Tiziana Life Sciences	N/A	1.02	1.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENGN enGene	64.16%
IMA ImageneBio	75.00%
OGI Organigram Global	34.63%
TLSA Tiziana Life Sciences	N/A

Insider Ownership

Company	Insider Ownership
ENGN enGene	10.40%
IMA ImageneBio	5.94%
OGI Organigram Global	0.09%
TLSA Tiziana Life Sciences	39.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENGN enGene	31	51.10 million	45.79 million	N/A
IMA ImageneBio	70	4.02 million	3.78 million	Not Optionable
OGI Organigram Global	860	134.05 million	133.93 million	Optionable
TLSA Tiziana Life Sciences	8	116.85 million	70.32 million	Optionable

IMA, OGI, TLSA, and ENGN Headlines

Recent News About These Companies

Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 7.4% - Time to Sell?

August 21, 2025 | marketbeat.com

Tiziana Life Sciences doses first MSA patient in new trial – ICYMI

August 15, 2025 | proactiveinvestors.com

Tiziana Life Sciences Initiates Phase 2a Trial for MSA with Intranasal Foralumab

August 14, 2025 | msn.com

Tiziana Life doses first patient in Phase 2a trial of intranasal foralumab

August 14, 2025 | msn.com

Tiziana Life Sciences doses first patient in Phase 2a MSA trial

August 14, 2025 | proactiveinvestors.com

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

August 14, 2025 | globenewswire.com

Tiziana Life Sciences Phase 2a multiple system atrophy study green-lit by FDA

August 11, 2025 | proactiveinvestors.com

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

August 11, 2025 | globenewswire.com

Dauntless Investment Group LLC Buys Shares of 1,739,574 Tiziana Life Sciences Ltd (NASDAQ:TLSA)

July 29, 2025 | marketbeat.com

Tiziana Life Sciences reports encouraging results from nasal Alzheimer's treatment

July 21, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

July 21, 2025 | globenewswire.com

Tiziana Life Sciences Ltd (TLSA) - Yahoo Finance

July 11, 2025 | finance.yahoo.com

Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting

June 13, 2025 | seekingalpha.com

Tiziana Life Sciences expands Phase 2 MS trial to fifth site, commences patient dosing

June 13, 2025 | proactiveinvestors.com

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

June 13, 2025 | globenewswire.com

Tiziana Life Sciences to Present at the Bio International Convention

June 13, 2025 | globenewswire.com

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

May 23, 2025 | finance.yahoo.com

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

May 23, 2025 | globenewswire.com

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 15, 2025 | finance.yahoo.com

Tiziana Life Sciences' foralumab reduced neuroinflammation in Alzheimer's patient, study shows

May 15, 2025 | proactiveinvestors.com

Tiziana Life Sciences reports purchase of shares by chairman

May 12, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IMA, OGI, TLSA, and ENGN Company Descriptions

enGene NASDAQ:ENGN

$4.62 -0.13 (-2.74%)

Closing price 04:00 PM Eastern

Extended Trading

$4.74 +0.12 (+2.68%)

As of 04:30 PM Eastern

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

ImageneBio NASDAQ:IMA

$13.40 -0.06 (-0.45%)

As of 04:00 PM Eastern

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Organigram Global NASDAQ:OGI

$1.73 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.71 -0.02 (-1.16%)

As of 05:33 PM Eastern

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.

Tiziana Life Sciences NASDAQ:TLSA

$1.81 -0.02 (-1.09%)

Closing price 04:00 PM Eastern

Extended Trading

$1.84 +0.02 (+1.38%)

As of 05:27 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time